{"output": [["Immunomedics", "COMP", "Announce", "Royalty Funding", "ECON_INDICATOR"], ["Immunomedics", "COMP", "Announce", "Stock Purchase Agreements", "ECON_INDICATOR"], ["Immunomedics", "COMP", "Relate_To", "Royalty Pharma", "ORG"], ["Royalty Pharma", "ORG", "Control", "Royalty Rights", "CONCEPT"], ["Royalty Pharma", "ORG", "Control", "Stock Purchase Agreements", "ECON_INDICATOR"], ["Royalty Pharma", "ORG", "Control", "$175 Mln", "ECON_INDICATOR"], ["Royalty Pharma", "ORG", "Control", "$75 Mln", "ECON_INDICATOR"], ["Royalty Pharma", "ORG", "Control", "Common Stock", "FIN_INSTRUMENT"], ["Immunomedics", "COMP", "Operate_In", "Global Net Sales", "ECON_INDICATOR"], ["Immunomedics", "COMP", "Produce", "Sacituzumab Govitecan", "PRODUCT"], ["Immunomedics", "COMP", "Operate_In", "All Indications", "CONCEPT"], ["Immunomedics", "COMP", "Impact", "Sufficient Cash", "ECON_INDICATOR"], ["Immunomedics", "COMP", "Impact", "Operations", "CONCEPT"], ["Immunomedics", "COMP", "Impact", "2020", "TIME"]], "published": "2018-01-08T15:40:00.000+02:00"}